Front. Nutr. Frontiers in Nutrition Front. Nutr. 2296-861X Frontiers Media S.A. 10.3389/fnut.2023.1274122 Nutrition Systematic Review Probiotics for the prevention and treatment of COVID-19: a rapid systematic review and meta-analysis Sohail Aruba 1 † Cheema Huzaifa Ahmad 2 * † Mithani Maidah Sohail 1 Shahid Abia 2 Nawaz Ahmad 2 Hermis Alaa Hamza 3 Chinnam Sampath 4 Nashwan Abdulqadir J. 5 * Cherrez-Ojeda Ivan 6 7 Awan Rehmat Ullah 8 ‡ Ahmad Sharjeel 9 ‡ 1Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan 2Division of Infectious Diseases, Department of Medicine, King Edward Medical University, Lahore, Pakistan 3Nursing Department, Al-Mustaqbal University College, Hillah, Babylon, Iraq 4Department of Chemistry, M. S. Ramaiah Institute of Technology (Affiliated to Visvesvaraya Technological University, Belgaum), Bengaluru, Karnataka, India 5Hamad Medical Corporation, Doha, Qatar 6Respiralab Research Center, Guayaquil, Ecuador 7Universidad Espíritu Santo, Guayaquil, Ecuador 8Department of Medicine, Ochsner Rush Medical Center, Meridian, MS, United States 9Department of Medicine, Section of Infectious Diseases, University of Illinois College of Medicine at Peoria, Peoria, IL, United States

Edited by: George Grant, University of Aberdeen, United Kingdom

Reviewed by: Giovanni Tarantino, University of Naples Federico II, Italy; Gabriella d'Ettorre, Sapienza University of Rome, Italy

 *Correspondence: Abdulqadir J. Nashwan, anashwan@hamad.qa Huzaifa Ahmad Cheema, huzaifaahmadcheema@gmail.com

†These authors have contributed equally to this work and share first authorship

‡These authors have contributed equally to this work and share senior authorship

 27 10 2023 2023 10 1274122 07 08 2023 02 10 2023 Copyright © 2023 Sohail, Cheema, Mithani, Shahid, Nawaz, Hermis, Chinnam, Nashwan, Cherrez-Ojeda, Awan and Ahmad. 2023 Sohail, Cheema, Mithani, Shahid, Nawaz, Hermis, Chinnam, Nashwan, Cherrez-Ojeda, Awan and Ahmad

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 Background

Although numerous modalities are currently in use for the treatment and prophylaxis of COVID-19, probiotics are a cost-effective alternative that could be used in diverse clinical settings. Hence, we conducted a meta-analysis to investigate the role of probiotics in preventing and treating COVID-19 infection.

 Methods

We searched several databases from inception to 30 May 2023 for all randomized controlled trials (RCTs) and comparative observational studies that evaluated probiotics (irrespective of the regimen) for the treatment or prevention of COVID-19. We conducted our meta-analysis using RevMan 5.4 with risk ratio (RR) and mean difference (MD) as the effect measures.

 Results

A total of 18 studies (11 RCTs and 7 observational studies) were included in our review. Probiotics reduced the risk of mortality (RR 0.40; 95% CI: 0.25–0.65, I2 = 0%). Probiotics also decreased the length of hospital stay, rate of no recovery, and time to recovery. However, probiotics had no effect on the rates of ICU admission. When used prophylactically, probiotics did not decrease the incidence of COVID-19 cases (RR 0.65; 95% CI: 0.37–1.12; I2 = 66%). The results for all outcomes were consistent across the subgroups of RCTs and observational studies (P for interaction >0.05).

 Conclusion

The results of this meta-analysis support the use of probiotics as an adjunct treatment for reducing the risk of mortality or improving other clinical outcomes in patients with COVID-19. However, probiotics are not useful as a prophylactic measure against COVID-19. Large-scale RCTs are still warranted for determining the most efficacious and safe probiotic strains.

 Systematic Review Registration

PROSPERO (CRD42023390275: https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=390275).

 probiotics COVID-19 SARS-CoV-2 synbiotics meta-analysis section-at-acceptance Nutrition and Microbes Introduction

New variants of COVID-19 continue to be reported worldwide significantly impacting morbidity and mortality. Thus, research to investigate novel treatment modalities still holds significance in the clinical setting. Numerous therapies have been investigated for treating COVID-19 (1, 2); however, questionable efficacy or safety, high costs, and the need for parenteral administration are among the issues that limit the widespread use of many of these agents (3–6). Probiotics can be a cost-effective alternative that could be used in diverse clinical settings.

Probiotics are defined as “live microorganisms that when administered in adequate amounts, confer a health benefit on the host (7).” Clinical trials have shown the efficacy of single or multiple strains of probiotics in the management of respiratory tract infections (8, 9). Recently, the use of probiotics for COVID-19 has also been proposed (10); however, the efficacy of probiotics in the treatment of COVID-19 remains inconclusive. Previous meta-analyses either did not include several key studies or only assessed the effect of probiotics on a limited number of clinical outcomes which limits the applicability of their findings (11–13). In this meta-analysis, we have thus included all the studies available in the literature to investigate the role of probiotics in preventing and treating COVID-19 infection.

 Methods

Our meta-analysis was registered with PROSPERO (CRD42023390275) and conducted by following the recommendations of Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) (14).

Search strategy

We searched MEDLINE (via PubMed), Embase, the Cochrane Library, and ClinicalTrials.gov from inception to 30 May 2023, without using any filters or restrictions. The search strategy consisted of the following terms: (“COVID-19′′ or “coronavirus disease 2019′′ or “novel coronavirus” or “SARS-CoV-2′′) AND (“probiotics” or “S. thermophilus” or “L.acidophilus” or “synbiotics” or “Lactobacillus rhamnosus GG” or “SIM01” or “Bifidobacterium”). Reference lists of relevant articles were also manually screened to retrieve additional relevant studies. A partial search of Google Scholar was conducted to find any relevant grey literature.

 Study selection and eligibility criteria

All the literature obtained from our searches was imported into Mendeley Desktop 1.19.8 and duplicates were removed. The remaining articles were subjected to a rigorous screening process by two independent reviewers. The inclusion criteria were: (1) study design: randomized controlled trials (RCTs) and comparative observational studies; (2) population: patients with COVID-19 irrespective of age or disease severity; (3) intervention: probiotics (irrespective of the regimen) used to treat or prevent COVID-19; and (4) comparator: placebo or standard care.

 Data extraction and outcomes

We extracted all information relating to the study characteristics such as author names, location, study population, details of intervention and comparator groups, and our outcomes of interest. The primary outcome was the risk of all-cause mortality, while the secondary outcomes included the rates of ICU admission, length of hospital stay, time to recovery, and the rate of no recovery. For studies that assessed the use of probiotics as a prophylactic measure against COVID-19, our outcome was the incidence of COVID-19 cases.

 Quality assessment

For the quality assessment, the revised Cochrane Risk of Bias Tool (RoB 2.0) (15) was used for RCTs, while the Newcastle Ottawa Scale (NOS) was used for observational studies (16).

 Data analysis

We conducted our meta-analysis using RevMan 5.4 with risk ratio (RR) and mean difference (MD) as the effect measures for categorical and continuous variables, respectively. We utilized a random-effects model as we anticipated our included studies to be substantially heterogeneous (17). We evaluated heterogeneity using the Chi2 test and the I2 statistic. We conducted a subgroup analysis for all of our outcomes on the basis of the type of study (RCT vs. observational study). In addition, we conducted a sensitivity analysis on our primary outcome by excluding Shah et al. (18) which combined probiotics with a systemic enzyme complex. We could not assess publication bias as no outcome included 10 studies or more.

 Results Search results and study characteristics

We included 18 studies (11 RCTs and 7 observational studies) in our review (18–35). The details of the screening process are presented in Figure 1.

PRISMA 2020 flowchart.

Most of the studies had small sample sizes while the retrospective cohort study by Louca et al. was the largest with 445,850 subjects (33). The studies employed a variety of probiotic regimens and most used standard of care as the comparator. The detailed characteristics of each study are presented in Supplementary Table S1.

 Risk of bias assessment

Two trials were at a high risk of bias, only one was at a low risk of bias, and the rest had some concerns of bias (Figure 2). The most frequent bias was in the randomization process. Of the observational studies, only two were deemed to be of high quality (Table 1).

Quality assessment of included trials.

Quality assessment of observational studies.

Study Selection Comparability Outcome Total
S1 S2 S3 S4 C O1 O2 O3
Li et al. (32) * * * * * * * 7*
Louca et al. (33) * * * * * * * 7*
Trinchieri et al. (24) * * * * * * * 7*
Zhang et al. (34) * * * * * * * * * 9*
Ceccarelli et al. (29) * * * * * * * * * 8*
Ceccarelli et al. (35) * * * * * * * 7*
d’Ettorre et al. (19) * * * * * * * 7*
Results of the meta-analysis

The results of our meta-analysis showed that probiotics reduced the risk of mortality (RR 0.40; 95% CI: 0.25–0.65, I2 = 0%; Figure 3).

Effect of probiotics on all-cause mortality in COVID-19 patients.

Probiotics had no effect on the rates of ICU admission (RR 0.79; 95% CI: 0.52–1.20; I2 = 0%; Supplementary Figure S1). The length of hospital stay was significantly reduced with probiotics (MD -2.52 days; 95% CI: −4.66 to −0.38 days; I2 = 67%; Supplementary Figure S2). Probiotics reduced the rate of no recovery (RR 0.66; 95% CI: 0.55–0.78; I2 = 0%; Supplementary Figure S3) and decreased the time to recovery (MD -2.18 days; 95% CI: −3.87 to −0.48 days; I2 = 82%; Supplementary Figure S4). When taken prophylactically, probiotics did not decrease the incidence of COVID-19 cases (RR 0.65; 95% CI: 0.37–1.12; I2 = 66%; Supplementary Figure S5). The results for all outcomes were consistent across the subgroups of RCTs and observational studies (P for interaction >0.05).

Sensitivity analysis by excluding Shah et al. (18) which combined probiotics with a systemic enzyme complex produced no significant changes in the results of the length of hospital stay (MD -3.47 days; 95% CI: −5.22 to −1.72 days; I2 = 0%) and recovery time (MD -2.49 days; 95% CI: −4.51 to −0.48 days; I2 = 83%).

 Discussion

To the best of our knowledge, this is the most comprehensive meta-analysis to date which evaluates the therapeutic efficacy of probiotics in treating and preventing COVID-19. A previous meta-analysis by Neris Almeida Viana et al. assessed only the symptomatic recovery of COVID-19 patients and did not include several large and important studies (11). Other meta-analyses also have an outdated search and did not include several recent studies (12, 13). Moreover, none of these meta-analyses evaluated the role of probiotics as a prophylactic therapy. In this study, we assessed several important clinical outcomes such as mortality and ICU admission, which increases the reliability of our conclusions regarding the efficacy of probiotics. The primary findings of our study indicate that probiotics are effective in reducing the risk of mortality in COVID-19 patients by 60%. Probiotics also decreased the duration of hospitalization and recovery time. However, no benefit was found when given as prophylaxis for COVID-19.

The effectiveness of probiotics in therapy can be explained through intricate pathways and potential anatomical connections, primarily involving the gut-lung axis (GLA) (36, 37). The mesenteric lymphatic system serves as the conduit between the intestines and the lungs, facilitating the passage of intact bacteria, their components, or metabolites across the intestinal barrier into the systemic circulation. This process can subsequently impact the immune response within the lungs (38, 39). Dysbiosis in the gut microbiota has been documented in individuals with COVID-19, and this dysbiosis may arise either as a result of the COVID-19 infection itself or due to the antiviral medications administered during treatment (40). Consequently, the use of probiotics in COVID-19 patients could potentially offer advantages in preserving the equilibrium of the gut microbiota (10). In addition to their effects within the gastrointestinal tract, probiotics have demonstrated the potential to confer health benefits through various mechanisms. These mechanisms encompass immunomodulation, the maintenance of epithelial barrier function, and the modulation of signal transduction pathways (41). Therefore, probiotics may improve the clinical outcomes in COVID-19 patients along with other COVID-19 symptoms like diarrhea.

Numerous treatment modalities such as antivirals, immunomodulatory agents, monoclonal antibodies, repurposed drugs, and herbal therapies have been investigated for COVID-19 since the beginning of the pandemic (42–46). However, many factors such as low availability, high costs, and questionable efficacy hinder their widespread use (2, 3, 47, 48). Thus, probiotics prove to be an efficacious, inexpensive, and readily available treatment alternative for COVID-19. However, the findings of our study do not support the use of probiotics for prophylaxis as the association with the incidence of COVID-19 cases was reported to be insignificant. Future research should evaluate the efficacy of probiotics against newer COVID-19 variants as well as comparative efficacy in relation to other treatment modalities.

Several limitations should be considered when interpreting the findings of our study. First, this is a pooled analysis of individual studies, and a patient-level analysis was not conducted as we did not have access to the individual patient data. Second, the inclusion of observational studies might have introduced confounding bias; however, this was mitigated by pooling RCTs separately from observational studies. Third, the considerable heterogeneity in the population and intervention across the included studies in terms of disease severity, and composition and dose of probiotics precluded any attempts to conduct subgroup analyses on these potential effect modifiers. Therefore, our results may not be generalizable to some probiotic strains or a spectrum of disease severity. Lastly, only a few included studies were of high quality as most demonstrated poor internal validity.

In conclusion, treatment with probiotics contributes to improved clinical outcomes including a decreased mortality rate and faster recovery. However, further large-scale trials are warranted for determining the most efficacious probiotic strains and regimens and evaluating the safety of these regimens.

 Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

 Author contributions

ArS: Conceptualization, Data curation, Formal analysis, Validation, Writing – original draft, Writing – review & editing. HC: Conceptualization, Data curation, Formal analysis, Writing – original draft, Writing – review & editing. MM: Formal analysis, Writing – original draft, Writing – review & editing. AbS: Data curation, Writing – original draft, Writing – review & editing. AhN: Formal analysis, Writing – original draft, Writing – review & editing. AH: Formal analysis, Writing – original draft, Writing – review & editing. SC: Writing – original draft, Writing – review & editing. AbN: Writing – original draft, Writing – review & editing. IC-O: Conceptualization, Writing – original draft, Writing – review & editing. RA: Conceptualization, Writing – original draft, Writing – review & editing. SA: Conceptualization, Writing – original draft, Writing – review & editing.

 Funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.

 Conflict of interest

AN was employed by Hamad Medical Corporation.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

 Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

 Supplementary material

The Supplementary material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fnut.2023.1274122/full#supplementary-material

 References Lamontagne F Agarwal A Rochwerg B Siemieniuk RA Agoritsas T Askie L . A living WHO guideline on drugs for covid-19. BMJ. (2020) 370:m3379. doi: 10.1136/bmj.m3379 Rayner CR Dron L Park JJH Decloedt EH Cotton MF Niranjan V . Accelerating clinical evaluation of repurposed combination therapies for COVID-19. Am J Trop Med Hyg. (2020) 103:1364–6. doi: 10.4269/ajtmh.20-0995, PMID: 32828137 Dal-Ré R Becker SL Bottieau E Holm S. Availability of oral antivirals against SARS-CoV-2 infection and the requirement for an ethical prescribing approach. Lancet Infect Dis. (2022) 22:e231–8. doi: 10.1016/s1473-3099(22)00119-0, PMID: 35364019 Fatima M Azeem S Saeed J Shahid A Cheema HA. Efficacy and safety of molnupiravir for COVID-19 patients. Eur J Intern Med. (2022) 102:118–21. doi: 10.1016/j.ejim.2022.05.024, PMID: 35649740 Cheema HA Jafar U Sohail A Shahid A Sahra S Ehsan M . Nirmatrelvir–ritonavir for the treatment of COVID-19 patients: a systematic review and meta-analysis. J Med Virol. (2023) 95:e28471. doi: 10.1002/jmv.28471 Cheema HA Ali A Ali M Shahid A Ghafoor MS Ur Rehman ME . Efficacy and safety of Favipiravir for the treatment of COVID-19 outpatients: a systematic review and meta-analysis of randomized controlled trials. Am J Ther. (2023). doi: 10.1097/MJT.0000000000001649, PMID: 37647511 Martín R Langella P. Emerging health concepts in the probiotics field: streamlining the definitions. Front Microbiol. (2019) 10:1047. doi: 10.3389/fmicb.2019.01047, PMID: 31164874 Zhao Y Dong BR Hao Q. Probiotics for preventing acute upper respiratory tract infections. Cochrane Database Syst Rev. (2022) 8:CD006895. doi: 10.1002/14651858.CD006895.pub4, PMID: 36001877 Cheema HA Shahid A Ayyan M Mustafa B Zahid A Fatima M . Probiotics for the prevention of ventilator-associated pneumonia: an updated systematic review and Meta-analysis of randomised controlled trials. Nutrients. (2022) 14:1600. doi: 10.3390/nu14081600, PMID: 35458162 Xavier-Santos D Padilha M Fabiano GA Vinderola G Gomes Cruz A Sivieri K . Evidences and perspectives of the use of probiotics, prebiotics, synbiotics, and postbiotics as adjuvants for prevention and treatment of COVID-19: a bibliometric analysis and systematic review. Trends Food Sci Technol. (2022) 120:174–92. doi: 10.1016/j.tifs.2021.12.033, PMID: 35002079 Neris Almeida Viana S do Reis Santos Pereira T de Carvalho Alves J Tianeze de Castro C Santana C Da Silva L Henrique Sousa Pinheiro L . Benefits of probiotic use on COVID-19: a systematic review and meta-analysis. Crit Rev Food Sci Nutr. (2022):1–13. doi: 10.1080/10408398.2022.2128713, PMID: 36178362 Wu J-Y Huang P-Y Liu T-H Kuo C-Y Tsai Y-W Tang H-J . Clinical efficacy of probiotics in the treatment of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials. Expert Rev Anti-Infect Ther. (2023) 21:667–74. doi: 10.1080/14787210.2023.2189100, PMID: 36881729 Zhu J Pitre T Ching C Zeraatkar D Gruchy S. Safety and efficacy of probiotic supplements as adjunctive therapies in patients with COVID-19: a systematic review and meta-analysis. PLoS One. (2023) 18:e0278356. doi: 10.1371/journal.pone.0278356, PMID: 37000812 Page MJ McKenzie JE Bossuyt PM Boutron I Hoffmann TC Mulrow CD . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. (2021) 372:n71. doi: 10.1136/bmj.n71, PMID: 33782057 Sterne JAC Savović J Page MJ Elbers RG Blencowe NS Boutron I . RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. (2019) 366:l4898. doi: 10.1136/bmj.l4898 Wells G Shea B O’Connell D Peterson J. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa: Ottawa Hosp Res Inst (2000) Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Borenstein M Hedges LV Higgins JPT Rothstein HR. A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Methods. (2010) 1:97–111. doi: 10.1002/jrsm.12, PMID: 26061376 Shah N Parate R Vispute A. Potential of the combination of a systemic enzyme complex and probiotics administration to combat COVID-19: a randomized open label prospective analysis. Adv Clin Toxicol. (2021) 6:205. doi: 10.23880/act-16000205 d'Ettorre G Ceccarelli G Marazzato M Campagna G Pinacchio C Alessandri F . Challenges in the management of SARS-CoV2 infection: the role of oral bacteriotherapy as complementary therapeutic strategy to avoid the progression of COVID-19. Front Med. (2020) 7:389. doi: 10.3389/fmed.2020.00389, PMID: 32733907 Gutiérrez-Castrellón P Gandara-Martí T Abreu AT AY Nieto-Rufino CD López-Orduña E Jiménez-Escobar I . Probiotic improves symptomatic and viral clearance in Covid19 outpatients: a randomized, quadruple-blinded, placebo-controlled trial. Gut Microbes. (2022) 14:2018899. doi: 10.1080/19490976.2021.2018899, PMID: 35014600 Navarro-López V Hernández-Belmonte A Pérez Soto MI Ayo-González M Losa-Rodríguez G Ros-Sánchez E . Oral intake of Kluyveromyces marxianus B0399 plus Lactobacillus rhamnosus CECT 30579 to mitigate symptoms in COVID-19 patients: a randomized open label clinical trial. Med Microecol. (2022) 14:100061. doi: 10.1016/J.MEDMIC.2022.100061 Rodriguez-Blanque R Sánchez-García JC Cobos-Vargas Á Aguilar Quesada A Maldonado-Lobón JA Olivares M . Evaluation of the effect of Loigolactobacillus coryniformis K8 CECT 5711 consumption in health care workers exposed to COVID-19. Front Nutr. (2022) 9:1771. doi: 10.3389/FNUT.2022.962566/BIBTEX Saviano A Potenza A Siciliano V Petruzziello C Tarli C Migneco A . COVID-19 pneumonia and gut inflammation: the role of a mix of three probiotic strains in reducing inflammatory markers and need for oxygen support. J Clin Med. (2022) 11:3758. doi: 10.3390/jcm11133758, PMID: 35807040 Trinchieri V Marazzato M Ceccarelli G Lombardi F Piccirilli A Santinelli L . Exploiting Bacteria for improving hypoxemia of COVID-19 patients. Biomedicine. (2022) 10:1851. doi: 10.3390/biomedicines10081851, PMID: 36009399 Wischmeyer PE Tang H Ren Y Bohannon L Ramirez ZE Andermann TM . Daily Lactobacillus probiotic versus placebo in COVID-19-exposed household contacts (PROTECT-EHC): a randomized clinical trial. medRxiv. (2022). doi: 10.1101/2022.01.04.21268275 Di Pierro F Iqtadar S Mumtaz SU Bertuccioli A Recchia M Zerbinati N . Clinical effects of Streptococcus salivarius K12 in hospitalized COVID-19 patients: results of a preliminary study. Microorganisms. (2022) 10:1926. doi: 10.3390/MICROORGANISMS10101926, PMID: 36296202 Ivashkin V Fomin V Moiseev S Brovko M Maslennikov R Ulyanin A . Efficacy of a probiotic consisting of Lacticaseibacillus rhamnosus PDV 1705, Bifidobacterium bifidum PDV 0903, Bifidobacterium longum subsp. infantis PDV 1911, and Bifidobacterium longum subsp. longum PDV 2301 in the treatment of hospitalized patients with COVID-19: a randomized controlled trial. Probiotics Antimicrob Proteins. (2023) 15:460–8. doi: 10.1007/s12602-021-09858-5, PMID: 34643888 Ahanchian H Ranjbar A Reihani H Yazdi AP Jafari SA Kiani MA . Synbiotic for prevention of SARS-Cov2 infection in high risk hospital staffs: a randomized controlled trial. Open J Nurs. (2021) 11:281–90. doi: 10.4236/OJN.2021.115025 Ceccarelli G Marazzato M Celani L Lombardi F Piccirilli A Mancone M . Oxygen sparing effect of bacteriotherapy in COVID-19. Nutrients. (2021) 13:2898. doi: 10.3390/nu13082898, PMID: 34445055 Di Pierro F Colombo M. The administration of S. salivarius K12 to children may reduce the rate of SARS-CoV-2 infection. Minerva Med. (2021) 112:514–6. doi: 10.23736/S0026-4806.21.07487-5, PMID: 33709676 Haran JP Zheng Y Knobil K Palma NA Lawrence JF Wingertzahn MA. Targeting the microbiome with KB109 in outpatients with mild to moderate COVID-19 reduced medically attended acute care visits and improved symptom duration in patients with comorbidities. medRxiv. (2021). doi: 10.1101/2021.03.26.21254422 Li Q Cheng F Xu Q Su Y Cai X Zeng F . The role of probiotics in coronavirus disease-19 infection in Wuhan: a retrospective study of 311 severe patients. Int Immunopharmacol. (2021) 95:107531. doi: 10.1016/J.INTIMP.2021.107531, PMID: 33714884 Louca P Murray B Klaser K Graham MS Mazidi M Leeming ER . Modest effects of dietary supplements during the COVID-19 pandemic: insights from 445 850 users of the COVID-19 symptom study app. BMJ Nutr Prev Health. (2021) 4:149–57. doi: 10.1136/bmjnph-2021-000250, PMID: 34308122 Zhang L Han H Li X Chen C Xie X Su G . Probiotics use is associated with improved clinical outcomes among hospitalized patients with COVID-19. Ther Adv Gastroenterol. (2021) 14:175628482110356. doi: 10.1177/17562848211035670, PMID: 34394726 Ceccarelli G Borrazzo C Pinacchio C Santinelli L Innocenti GP Cavallari EN . Oral bacteriotherapy in patients with COVID-19: a retrospective cohort study. Front Nutr. (2021) 7:341. doi: 10.3389/fnut.2020.613928, PMID: 33505983 Li N Ma W-T Pang M Fan Q-L Hua J-L. The commensal microbiota and viral infection: a comprehensive review. Front Immunol. (2019) 10:10. doi: 10.3389/fimmu.2019.01551 Enaud R Prevel R Ciarlo E Beaufils F Wieërs G Guery B . The gut-lung axis in health and respiratory diseases: a place for inter-organ and inter-kingdom crosstalks. Front Cell Infect Microbiol. (2020) 10:9. doi: 10.3389/fcimb.2020.00009, PMID: 32140452 Bingula R Filaire M Radosevic-Robin N Bey M Berthon J-Y Bernalier-Donadille A . Desired turbulence? Gut-lung axis, immunity, and lung cancer. J Oncol. (2017) 2017:5035371–15. doi: 10.1155/2017/5035371, PMID: 29075294 McAleer JP Kolls JK. Contributions of the intestinal microbiome in lung immunity. Eur J Immunol. (2018) 48:39–49. doi: 10.1002/eji.201646721, PMID: 28776643 Aguila EJT Lontok MADC Aguila EJT. Letter: role of probiotics in the COVID-19 pandemic. Aliment Pharmacol Ther. (2020) 52:931–2. doi: 10.1111/apt.15898, PMID: 32852829 Wan LYM Chen ZJ Shah NP El-Nezami H. Modulation of intestinal epithelial defense responses by probiotic Bacteria. Crit Rev Food Sci Nutr. (2016) 56:2628–41. doi: 10.1080/10408398.2014.905450, PMID: 25629818 Forrest JI Rayner CR Park JJH Mills EJ. Early treatment of COVID-19 disease: a missed opportunity. Infect Dis Ther. (2020) 9:715–20. doi: 10.1007/s40121-020-00349-8, PMID: 33051827 Cheema HA Shafiee A Athar MMT Shahid A Awan RU Afifi AM . No evidence of clinical efficacy of famotidine for the treatment of COVID-19: a systematic review and meta-analysis. J Infect. (2023) 86:154–225. doi: 10.1016/j.jinf.2022.11.022, PMID: 36462586 Cheema HA Jafar U Elrashedy AA Shahid A Awan RU Ehsan M . Efficacy and safety of fluvoxamine for the treatment of COVID-19 patients: a systematic review and meta-analysis. J Infect. (2022) 85:702–69. doi: 10.1016/j.jinf.2022.10.012, PMID: 36244547 Wang J Levi J Ellis L Hill A. Minimum manufacturing costs, national prices, and estimated global availability of new repurposed therapies for coronavirus disease 2019. Open Forum Infect Dis. (2022) 9:ofab581. doi: 10.1093/ofid/ofab581, PMID: 34988252 Cheema HA Sohail A Fatima A Shahid A Shahzil M Ur Rehman ME . Quercetin for the treatment of COVID-19 patients: a systematic review and meta-analysis. Rev Med Virol. (2023) 33:e2427. doi: 10.1002/rmv.2427, PMID: 36779438 Fatima U Rizvi SSA Raina N Fatima S Rahman S Kamal MA . Therapeutic management of COVID-19 patients: clinical manifestation and limitations. Curr Pharm Des. (2021) 27:4223–31. doi: 10.2174/1381612826666201125112719 Sharun K Tiwari R Yatoo MI Natesan S Megawati D Singh KP . A comprehensive review on pharmacologic agents, immunotherapies and supportive therapeutics for COVID-19. Narra J. (2022) 2:e92–2. doi: 10.52225/NARRA.V2I3.92